1-(3,5-二氟-4-甲氧基苄基)-2-巯基咪唑 | 104197-16-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(3,5-二氟-4-甲氧基苄基)-2-巯基咪唑
• 英文名称: 1-(4'-methoxy-3',5'-difluorobenzyl)-1,3-dihydro-2H-imidazole-2-thione
• 英文别名: 1-(3,5-Difluoro-4-methoxybenzyl)-2-mercaptoimidazole；3-[(3,5-difluoro-4-methoxyphenyl)methyl]-1H-imidazole-2-thione
• CAS: 104197-16-2
• 化学式: C₁₁H₁₀F₂N₂OS
• 分子量: 256.276
• InChiKey: JGGJPPRXUFKTAU-UHFFFAOYSA-N

物化性质

• 沸点：
  350.3±52.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  56.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(3,5-二氟-4-甲氧基苄基)-2-巯基咪唑 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 1-(4'-hydroxy-3',5'-difluorobenzyl)-1,3-dihydro-2H-imidazole-2-thione
  参考文献：
  名称：

  Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site

  摘要：

  1-Aralkylimidazole-2-thiones have been shown to be potent multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1). In the present study, a series of 1-benzylimidazole-2-thiones was prepared to explore the effects of substitution in the benzyl ring on the inhibition of DBH. A detailed structure-activity relationship for in vitro activity was discovered and this was shown by a modified Hansch analysis to correlate (r = 0.91) with four key structural features of the benzyl ring: the presence of a hydroxyl at the 4-position, molar refractivity at the 3-, 4-, and 5-positions, inductive effects of the substituents at the 3-, 4-, and 5-positions, and pi-electron density. The affinity (Kis) of eight substituted inhibitors for DBH was shown to correlate (r = 0.75) with the affinity (KD) of comparably substituted tyramines for the ternary DBH-oxygen-tyramine complex. This correlate is used to support the hypothesis that binding of inhibitor to DBH occurs in a fashion that mimics the binding of tyramine substrates. The most potent inhibitors were selected for study in vivo in the spontaneously hypertensive rat model of hypertension. The changes in vascular dopamine and norepinephrine levels that resulted from oral administration of the inhibitors corresponded to the observed reduction in mean arterial blood pressure. A divergence between in vitro potency and in vivo efficacy upon oral dosing was noted and is suggested to result from an in vivo metabolic conjugation of the phenolic group of inhibitor.

  DOI：

  10.1021/jm00386a008
• 作为产物：
  描述：

  N-(3,5-二氟-4-甲氧基苄基)-氨基乙醛二甲基缩醛 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 生成 1-(3,5-二氟-4-甲氧基苄基)-2-巯基咪唑
  参考文献：
  名称：

  Dopamine-.beta.-hydroxylase inhibitors

  摘要：

  具有以下结构式##STR1##的强效DBH抑制剂可用于抑制哺乳动物中的DBH活性。

  公开号：

  US04992459A1

文献信息

• Ester prodrugs of dopamine-.beta.-hydroxylase, inhibitors, composition
  申请人：SmithKline Beckman Corporation

  公开号：US04743613A1

  公开（公告）日：1988-05-10

  Compounds having the formula: ##STR1## which are ester prodrugs of potent dopamine-.beta.-hydroxylase inhibitors and thus are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmeceutical compositions including these compounds, and methods of using these compounds to inhibit dopamine-.beta.-hydroxylase activity in mammals.

  具有以下化学式的化合物：## STR1 ##，它们是有效的多巴胺-β-羟化酶抑制剂的酯前药，因此可用于抑制哺乳动物中的多巴胺-β-羟化酶活性，包括这些化合物的制药组合物，以及使用这些化合物抑制哺乳动物中的多巴胺-β-羟化酶活性的方法。
• Ester prodrugs of dopamine-beta-hydroxylase inhibitors
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0244956A1

  公开（公告）日：1987-11-11

  Compounds of structure (I) in which: Y is hydrogen, halogen, C1-4 haloalkyl, or any synthetically accessible combination thereof of up to four substituents; R is -wherein R1 is hydrogen or C1-4 alkyl: R2 is R or C1-4 alkyl; n is 0-4; or a pharmaceutically acceptable salt or hydrate thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy as dopamine β-hydroxylase inhibitors.

  结构(I)的化合物 其中 Y 是氢、卤素、C1-4 卤代烷基或最多四个取代基的任何合成组合； R 是 -其中 R1 是氢或 C1-4 烷基： R2 是 R 或 C1-4 烷基； n 为 0-4；或 它们的药学上可接受的盐或水合物、它们的制备工艺、含有它们的药物组合物以及它们作为多巴胺 β-羟化酶抑制剂在治疗中的用途。
• Dopamine-Beta-hydroxylase inhibitors
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0260814A1

  公开（公告）日：1988-03-23

  Potent DBH inhibitors having the formula be used to inhibit DBH activity in mammals.

  具有以下式子的强效 DBH 抑制剂 用于抑制哺乳动物体内的 DBH 活性。
• Dopamine-beta-hydroxylase inhibitors
  申请人：SMITHKLINE BECKMAN CORPORATION

  公开号：EP0323146A2

  公开（公告）日：1989-07-05

  Compounds of formula (I) and pharmaceutically acceptable salts or hydrates thereof are described in which, X is H, F, Cl, Br, I, C₁₋₄alkyl, CN, NO₂, SO₂NH₂, COOH, OH, CHO, C₁₋₄alkoxy, CH₂OH, CH₂OC₁₋₄alkyl, CF₃, C₂F₅, C₃F₇, SO₂CH₃, SO₂CF₃, or CO₂CaH2a+1 wherein a is 1 to 5, or any accessible combination thereof up to 5 substituents; n is 0 to 5; m is 1 to 5; R is H or C₁₋₄alkyl. These compounds are dopamine-β-hydroxylase inhibitors. Pharmaceutical compositions are described as are methods of use. Processes for the preparation of these compounds are described.

  式(I)化合物 及其药学上可接受的盐或水合物，其中，X 是 H、F、Cl、Br、I、C₁₋₄烷基、CN、NO₂、SO₂NH₂、COOH、OH、CHO、C₁₋₄烷氧基、CH₂OH、CH₂OC₁₋₄烷基、CF₃、C₂F₅、C₃F₇、SO₂CH₃、SO₂CF₃或 CO₂CaH2a+1，其中 a 为 1 至 5，或其中最多 5 个取代基的任何可获得的组合；n 为 0 至 5；m 为 1 至 5；R 为 H 或 C₁₋₄ 烷基。 这些化合物是多巴胺-β-羟化酶抑制剂。药剂组合物和使用方法均有描述。还描述了制备这些化合物的工艺。
• Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine .beta.-hydroxylase
  作者：Lawrence I. Kruse、Carl Kaiser、Walter E. DeWolf、James S. Frazee、Robert W. Erickson、Mildred Ezekiel、Eliot H. Ohlstein、Robert R. Ruffolo、Barry A. Berkowitz

  DOI：10.1021/jm00156a002

  日期：1986.6